Beam Therapeutics Inc. (BEAM) income statement
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3012% below fair value
$20.90−0.04 (-0.19%)
Close on Nov 20, 2026Market cap $2.16BP/E –Yield –
Beam Therapeutics Inc. financial ratios
See a number that looks wrong?